201 related articles for article (PubMed ID: 16411132)
1. CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions.
Gütgemann I; Haas S; Berg JP; Zhou H; Büttner R; Fischer HP
Virchows Arch; 2006 Apr; 448(4):407-11. PubMed ID: 16411132
[TBL] [Abstract][Full Text] [Related]
2. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions.
Bertram S; Padden J; Kälsch J; Ahrens M; Pott L; Canbay A; Weber F; Fingas C; Hoffmann AC; Vietor A; Schlaak JF; Eisenacher M; Reis H; Sitek B; Baba HA
J Clin Pathol; 2016 Jul; 69(7):619-26. PubMed ID: 26729014
[TBL] [Abstract][Full Text] [Related]
3. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma.
Haas S; Gütgemann I; Wolff M; Fischer HP
Am J Surg Pathol; 2007 Jun; 31(6):902-6. PubMed ID: 17527078
[TBL] [Abstract][Full Text] [Related]
4. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical profile of the so-called bile duct adenoma: clues to pathogenesis.
Hughes NR; Goodman ZD; Bhathal PS
Am J Surg Pathol; 2010 Sep; 34(9):1312-8. PubMed ID: 20679879
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
Sasaki M; Nakanuma Y; Ho SB; Kim YS
Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202
[TBL] [Abstract][Full Text] [Related]
7. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
8. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
[TBL] [Abstract][Full Text] [Related]
9. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
10. Hilar bile duct cancer associated with preoperatively undetectable von Meyenburg complex--report of a case.
Eguchi S; Tajima Y; Yanaga K; Okudaira S; Furui J; Hayashi T; Kanematsu T
Hepatogastroenterology; 2004; 51(59):1301-3. PubMed ID: 15362738
[TBL] [Abstract][Full Text] [Related]
11. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions.
Tretiakova M; Antic T; Westerhoff M; Mueller J; Himmelfarb EA; Wang HL; Xiao SY
Am J Surg Pathol; 2012 Jan; 36(1):101-8. PubMed ID: 21989348
[TBL] [Abstract][Full Text] [Related]
13. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
14. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas.
Mosnier JF; Kandel C; Cazals-Hatem D; Bou-Hanna C; Gournay J; Jarry A; Laboisse CL
Mod Pathol; 2009 Feb; 22(2):182-90. PubMed ID: 18622386
[TBL] [Abstract][Full Text] [Related]
15. Role of CD56-expressing immature biliary epithelial cells in biliary atresia.
Zhang RZ; Yu JK; Peng J; Wang FH; Liu HY; Lui VC; Nicholls JM; Tam PK; Lamb JR; Chen Y; Xia HM
World J Gastroenterol; 2016 Feb; 22(8):2545-57. PubMed ID: 26937142
[TBL] [Abstract][Full Text] [Related]
16. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
[TBL] [Abstract][Full Text] [Related]
17. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.
Tsokos CG; Krings G; Yilmaz F; Ferrell LD; Gill RM
Hum Pathol; 2016 Nov; 57():61-67. PubMed ID: 27396933
[TBL] [Abstract][Full Text] [Related]
18. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.
Sirica AE; Radaeva S; Caran N
Am J Pathol; 1997 Dec; 151(6):1685-94. PubMed ID: 9403719
[TBL] [Abstract][Full Text] [Related]
19. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
20. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness.
Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A
Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
